Boston, MA – January 24, 2023 – Cerevance, a private, clinical-stage drug discovery and development
company focused on central nervous system (CNS) diseases, today announced that Craig Thompson, chief
executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference. The
conference is being held virtually January 31 – February 2, 2023.
Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance’s
lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6),
demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients
with Parkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing
(NETSseq) technology platform to identify highly selectively expressed, novel target proteins that are
either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering
with over 25 brain banks and evaluating more than 12,000 human post-mortem brain tissue samples,
Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative
diseases, including Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For
additional information, please visit www.cerevance.com.
Johnna Simoes, firstname.lastname@example.org
Andrew Mielach, email@example.com, +1-646-876-5868